Open Access<p>Indole-2-Carboxamide Derivative LG25 Inhibits Triple-Negative Breast Cancer Growth By Suppressing Akt/mTOR/NF-κB Signalling Pathway</p>
Author(s) -
Xiaohong Xu,
Vinothkumar Rajamanickam,
Shengqiang Shu,
Zhoudi Liu,
Tao Yan,
Jinxin He,
Zhiguo Liu,
Gui-Long Guo,
Guang Liang,
Yi Wang
Publication year - 2019
Publication title -
drug design, development and therapy
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s216542
Subject(s) - pi3k/akt/mtor pathway , protein kinase b , triple negative breast cancer , viability assay , cancer research , apoptosis , clonogenic assay , mtt assay , cell cycle checkpoint , cell cycle , chemistry , cell growth , cancer , pharmacology , medicine , breast cancer , biology , biochemistry
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer which is associated with poor patient outcome and lack of targeted therapy. Our laboratory has synthesized a series of indole-2-carboxamide derivatives. Among this series, compound LG25 showed a favorable pharmacological profile against sepsis and inflammatory diseases. In the present study, we investigated the chemotherapeutic potential of LG25 against TNBC utilizing in vitro and in vivo models.